Literature DB >> 23744582

Ribosomal and hematopoietic defects in induced pluripotent stem cells derived from Diamond Blackfan anemia patients.

Loïc Garçon1, Jingping Ge, Shwetha H Manjunath, Jason A Mills, Marisa Apicella, Shefali Parikh, Lisa M Sullivan, Gregory M Podsakoff, Paul Gadue, Deborah L French, Philip J Mason, Monica Bessler, Mitchell J Weiss.   

Abstract

Diamond Blackfan anemia (DBA) is a congenital disorder with erythroid (Ery) hypoplasia and tissue morphogenic abnormalities. Most DBA cases are caused by heterozygous null mutations in genes encoding ribosomal proteins. Understanding how haploinsufficiency of these ubiquitous proteins causes DBA is hampered by limited availability of tissues from affected patients. We generated induced pluripotent stem cells (iPSCs) from fibroblasts of DBA patients carrying mutations in RPS19 and RPL5. Compared with controls, DBA fibroblasts formed iPSCs inefficiently, although we obtained 1 stable clone from each fibroblast line. RPS19-mutated iPSCs exhibited defects in 40S (small) ribosomal subunit assembly and production of 18S ribosomal RNA (rRNA). Upon induced differentiation, the mutant clone exhibited globally impaired hematopoiesis, with the Ery lineage affected most profoundly. RPL5-mutated iPSCs exhibited defective 60S (large) ribosomal subunit assembly, accumulation of 12S pre-rRNA, and impaired erythropoiesis. In both mutant iPSC lines, genetic correction of ribosomal protein deficiency via complementary DNA transfer into the "safe harbor" AAVS1 locus alleviated abnormalities in ribosome biogenesis and hematopoiesis. Our studies show that pathological features of DBA are recapitulated by iPSCs, provide a renewable source of cells to model various tissue defects, and demonstrate proof of principle for genetic correction strategies in patient stem cells.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23744582      PMCID: PMC3739037          DOI: 10.1182/blood-2013-01-478321

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  49 in total

1.  Clinical and laboratory evidence for a trilineage haematopoietic defect in patients with refractory Diamond-Blackfan anaemia.

Authors:  N Giri; E Kang; J F Tisdale; D Follman; M Rivera; G N Schwartz; S Kim; N S Young; M E Rick; C E Dunbar
Journal:  Br J Haematol       Date:  2000-01       Impact factor: 6.998

Review 2.  Fetal Diamond-Blackfan anemia associated with hydrops fetalis.

Authors:  Alston E Dunbar; Sheila L Moore; Roger M Hinson
Journal:  Am J Perinatol       Date:  2003-10       Impact factor: 1.862

3.  Development of the hemangioblast defines the onset of hematopoiesis in human ES cell differentiation cultures.

Authors:  Marion Kennedy; Sunita L D'Souza; Macarena Lynch-Kattman; Staci Schwantz; Gordon Keller
Journal:  Blood       Date:  2007-04-01       Impact factor: 22.113

4.  Expression of ribosomal protein genes cloned in a hybrid plasmid in Escherichia coli: gene dosage effects on synthesis of ribosomal proteins and ribosomal protein messenger ribonucleic acid.

Authors:  A M Fallon; C S Jinks; M Yamamoto; M Nomura
Journal:  J Bacteriol       Date:  1979-05       Impact factor: 3.490

5.  Impaired ribosome biogenesis in Diamond-Blackfan anemia.

Authors:  Valérie Choesmel; Daniel Bacqueville; Jacques Rouquette; Jacqueline Noaillac-Depeyre; Sébastien Fribourg; Aurore Crétien; Thierry Leblanc; Gil Tchernia; Lydie Da Costa; Pierre-Emmanuel Gleizes
Journal:  Blood       Date:  2006-10-19       Impact factor: 22.113

6.  Human RPS19, the gene mutated in Diamond-Blackfan anemia, encodes a ribosomal protein required for the maturation of 40S ribosomal subunits.

Authors:  Johan Flygare; Anna Aspesi; Joshua C Bailey; Koichi Miyake; Jacqueline M Caffrey; Stefan Karlsson; Steven R Ellis
Journal:  Blood       Date:  2006-09-21       Impact factor: 22.113

7.  Targeted disruption of the ribosomal protein S19 gene is lethal prior to implantation.

Authors:  Hans Matsson; Edward J Davey; Natalia Draptchinskaia; Isao Hamaguchi; Andreas Ooka; Per Levéen; Erik Forsberg; Stefan Karlsson; Niklas Dahl
Journal:  Mol Cell Biol       Date:  2004-05       Impact factor: 4.272

8.  RNA and protein evidence for haplo-insufficiency in Diamond-Blackfan anaemia patients with RPS19 mutations.

Authors:  Hanna T Gazda; Rong Zhong; Lilia Long; Edyta Niewiadomska; Jeffrey M Lipton; Anna Ploszynska; Jan M Zaucha; Adrianna Vlachos; Evangelia Atsidaftos; David H Viskochil; Charlotte M Niemeyer; Joerg J Meerpohl; Roma Rokicka-Milewska; Dagmar Pospisilova; W Wiktor-Jedrzejczak; David G Nathan; Alan H Beggs; Colin A Sieff
Journal:  Br J Haematol       Date:  2004-10       Impact factor: 6.998

9.  The accumulation of three yeast ribosomal proteins under conditions of excess mRNA is determined primarily by fast protein decay.

Authors:  E Maicas; F G Pluthero; J D Friesen
Journal:  Mol Cell Biol       Date:  1988-01       Impact factor: 4.272

10.  Cells depleted for RPS19, a protein associated with Diamond Blackfan Anemia, show defects in 18S ribosomal RNA synthesis and small ribosomal subunit production.

Authors:  Rachel A Idol; Sara Robledo; Hong-Yan Du; Dan L Crimmins; David B Wilson; Jack H Ladenson; Monica Bessler; Philip J Mason
Journal:  Blood Cells Mol Dis       Date:  2007-03-21       Impact factor: 3.039

View more
  41 in total

Review 1.  Osteosarcoma: Molecular Pathogenesis and iPSC Modeling.

Authors:  Yu-Hsuan Lin; Brittany E Jewell; Julian Gingold; Linchao Lu; Ruiying Zhao; Lisa L Wang; Dung-Fang Lee
Journal:  Trends Mol Med       Date:  2017-07-20       Impact factor: 11.951

2.  Molecular convergence in ex vivo models of Diamond-Blackfan anemia.

Authors:  Kelly A O'Brien; Jason E Farrar; Adrianna Vlachos; Stacie M Anderson; Crystiana A Tsujiura; Jens Lichtenberg; Lionel Blanc; Eva Atsidaftos; Abdel Elkahloun; Xiuli An; Steven R Ellis; Jeffrey M Lipton; David M Bodine
Journal:  Blood       Date:  2017-04-04       Impact factor: 22.113

3.  Confounding in ex vivo models of Diamond-Blackfan anemia.

Authors:  Jacob C Ulirsch; Caleb Lareau; Leif S Ludwig; Narla Mohandas; David G Nathan; Vijay G Sankaran
Journal:  Blood       Date:  2017-06-14       Impact factor: 22.113

4.  Utilization of the AAVS1 safe harbor locus for hematopoietic specific transgene expression and gene knockdown in human ES cells.

Authors:  Amita Tiyaboonchai; Helen Mac; Razveen Shamsedeen; Jason A Mills; Siddarth Kishore; Deborah L French; Paul Gadue
Journal:  Stem Cell Res       Date:  2014-02-21       Impact factor: 2.020

Review 5.  Current status of pluripotent stem cells: moving the first therapies to the clinic.

Authors:  Erin A Kimbrel; Robert Lanza
Journal:  Nat Rev Drug Discov       Date:  2015-09-22       Impact factor: 84.694

Review 6.  Modeling Human Bone Marrow Failure Syndromes Using Pluripotent Stem Cells and Genome Engineering.

Authors:  Moonjung Jung; Cynthia E Dunbar; Thomas Winkler
Journal:  Mol Ther       Date:  2015-10-05       Impact factor: 11.454

Review 7.  Li-Fraumeni Syndrome Disease Model: A Platform to Develop Precision Cancer Therapy Targeting Oncogenic p53.

Authors:  Ruoji Zhou; An Xu; Julian Gingold; Louise C Strong; Ruiying Zhao; Dung-Fang Lee
Journal:  Trends Pharmacol Sci       Date:  2017-08-14       Impact factor: 14.819

8.  Patient-Specific iPSC-Derived Endothelial Cells Provide Long-Term Phenotypic Correction of Hemophilia A.

Authors:  Cristina Olgasi; Maria Talmon; Simone Merlin; Alessia Cucci; Yvonne Richaud-Patin; Gabriella Ranaldo; Donato Colangelo; Federica Di Scipio; Giovanni N Berta; Chiara Borsotti; Federica Valeri; Francesco Faraldi; Maria Prat; Maria Messina; Piercarla Schinco; Angelo Lombardo; Angel Raya; Antonia Follenzi
Journal:  Stem Cell Reports       Date:  2018-11-08       Impact factor: 7.765

9.  Using induced human pluripotent stem cells to study Diamond-Blackfan anemia: an outlook on the clinical possibilities.

Authors:  Philip J Mason; Nieves Perdigones; Monica Bessler
Journal:  Expert Rev Hematol       Date:  2013-12       Impact factor: 2.929

Review 10.  De novo generation of HSCs from somatic and pluripotent stem cell sources.

Authors:  Linda T Vo; George Q Daley
Journal:  Blood       Date:  2015-03-11       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.